Revista do Grupo de Estudos do Cancro do Pulmão最新文献

{"title":"Osimertinib-induced cutaneous vasculitis: A case report and review of the literature","authors":"","doi":"10.32932/gecp.2023.10.038","DOIUrl":"https://doi.org/10.32932/gecp.2023.10.038","url":null,"abstract":"A 77-year-old patient with a history of stage IVa (cT4N3M1a) lung adenocarcinoma, treated with osimertinib 80 mg/ day, developed palpable purpura nine days after starting therapy. Skin biopsy revealed leukocytoclastic vasculitis. A complete clinical and lab workup for systemic involvement was unremarkable. The patient suspended osimertinib and started on methylprednisone 1mg/Kg/day. Skin lesions gradually improved. Four weeks apart, the patient resumed","PeriodicalId":484795,"journal":{"name":"Revista do Grupo de Estudos do Cancro do Pulmão","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136184807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic Body Radiation Therapy (SBRT): An optimal approach in the treatment of lung cancer and pulmonary metastases – a Portuguese center experience","authors":"","doi":"10.32932/gecp.2023.10.036","DOIUrl":"https://doi.org/10.32932/gecp.2023.10.036","url":null,"abstract":"Stereotactic Body Radiation Therapy (SBRT) is a noninvasive, safe, and effective treatment for early-stage lung cancer and metastatic lung disease in selected patients. Although there is no current consensus on the ideal dose http://doi.org/10.32932/gecp.2023.10.036","PeriodicalId":484795,"journal":{"name":"Revista do Grupo de Estudos do Cancro do Pulmão","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136184805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2013 e a imunoterapia em neoadjuvância no estádio precoce","authors":"","doi":"10.32932/gecp.2023.10.041","DOIUrl":"https://doi.org/10.32932/gecp.2023.10.041","url":null,"abstract":"","PeriodicalId":484795,"journal":{"name":"Revista do Grupo de Estudos do Cancro do Pulmão","volume":"162 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136184814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil-to-lymphocyte ratio as a prognostic marker in highly PD-L1 expressing advanced non-small cell lung cancer patients in first line treatment with pembrolizumab","authors":"","doi":"10.32932/gecp.2023.10.037","DOIUrl":"https://doi.org/10.32932/gecp.2023.10.037","url":null,"abstract":"Introduction and objectives: The neutrophil-lymphocyte ratio (NLR) has been proposed to assess advanced stage non-small cell lung cancer (aNSCLC) response to immunotherapy, given the easy availability and low cost. The aim of our study was to evaluate the relationship between NLR at baseline, after the 3 rd and 6 th treatment cycles, and progression free survival (PFS) and overall survival (OS), in a population with aNSCLC with a PD-L1 expression ≥50% treated with pembrolizumab monotherapy in first line. Methods: We performed a retrospective study of patients with aNSCLC with PD-L1≥50% who were treated with pembrolizumab first line from February 2017 to July 2021. NLR values at baseline and after the 3 rd and 6 th pembroli-zumab cycles were analyzed. Optimal NLR cut-off were determined with respect to OS, by ROC curve. PFS and OS were compared by Kaplan Meyer method and Cox Proportional Hazard model for NLR measures. Results: Sixty-six patients with PD-L1≥50% (51% males, mean age 65.8 ± 11.2 years) were included in the study. The PD-L1 expression was ≥90% in 74% of the patients. NLR≤4 after the 3 rd pembrolizumab cycle were associated with a significant improvement in PFS (23.6 vs 4.3 months, p=0.002) and OS (32.9 vs 6.3 months, p=0.022), compared with NLR>4. Discussion and conclusions: In patients with aNSCLC and a PD-L1≥50% receiving frontline pembrolizumab treatment, low NLR values after the 3 rd pembrolizumab cycle were associated with significantly longer PFS and OS. This biomarker may thus help identify individuals on pembrolizumab monotherapy who are at greatest risk for disease progression.","PeriodicalId":484795,"journal":{"name":"Revista do Grupo de Estudos do Cancro do Pulmão","volume":"162 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136184631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A humanização na doença oncológica","authors":"","doi":"10.32932/gecp.2023.10.040","DOIUrl":"https://doi.org/10.32932/gecp.2023.10.040","url":null,"abstract":"","PeriodicalId":484795,"journal":{"name":"Revista do Grupo de Estudos do Cancro do Pulmão","volume":"1164 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136184815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief fatigue inventory as a fatigue identification scale in lung cancer patients under immunotherapy – A real-life study","authors":"","doi":"10.32932/gecp.2023.10.035","DOIUrl":"https://doi.org/10.32932/gecp.2023.10.035","url":null,"abstract":"Introduction: Lung cancer (LC) is one of the most frequent oncological diseases in the world, and the use of immunotherapy is a substantial progress regarding new therapeutic options. Fatigue is the most frequently reported adverse effect in patients starting immunotherapy treatment, but it remains underdiagnosed. The purpose of this study was to identify whether the assessment of fatigue, recorded by the clinical team in the pulmonology consultation, agrees with that reported by patients with Non-Small Cell Lung Cancer (NSCLC), when answering the Brief Fatigue Inventory (BFI) questionnaire during treatment with immunotherapy alone or in combination with chemotherapy. Methods: A prospective observational study was conducted over 8 months. The research took place through the collection of medical records from the clinical files of the patients and the application of the BFI questionnaire, before each of 4 treatment cycles. Results: The sample consisted of 31 patients with 26 males and 5 females, with a mean age of 68.5 years. The mean value of the BFI score before the 1st treatment, as well as in the following 3 evaluations, was higher for the participants who presented symptoms of asthenia/tiredness/fatigue recorded in the clinical files at the consultation and lower for those who did not. However, the differences were not statistically significant (pre 1st treatment - p=0.299, pre 2nd treatment - p=0.125, pre 3rd treatment - p=0.103 and pre 4th treatment-p=0.954). By comparing the BFI questionnaire score with the medical records, we found that fatigue remained underreported in the consultation at the different evaluation moments (75.9% of the sample participants were not identified with fatigue at the 1st moment of evaluation; 75% at the pre-2nd treatment consultation; 81.2% at the pre-3rd treatment consulta-tion and 88.9% at the pre-4th treatment consultation). Conclusions: The benefit of applying the BFI questionnaire was relevant. This tool allowed the identification and stratification of fatigue, demonstrating greater sensitivity when compared only with the medical records of the con-sultation. The fact that the study sample was small was a limitation and made it difficult to obtain more robust results. Therefore, it is desirable to carry out more prospective, long-term studies in this area, to consolidate the results found in the present investigation.","PeriodicalId":484795,"journal":{"name":"Revista do Grupo de Estudos do Cancro do Pulmão","volume":"179 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136185020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When the stenting in the approach to superior vena cava syndrome allows radical treatment of non-small cell lung cancer at the diagnosis","authors":"","doi":"10.32932/gecp.2023.10.039","DOIUrl":"https://doi.org/10.32932/gecp.2023.10.039","url":null,"abstract":"Superior vena cava syndrome is an oncological emergency. It is life-threatening in 15% of the cases. When it is severe and the presentation form of malignancy, a multidisciplinary diagnostic and therapeutic approach is challenging and urgent. We present the case of a patient with no previous cancer that came to the emergency department due to superior vena cava syndrome. He had oedema of the face, cervical region and upper limbs, dyspnoea and altered mental status. Chest computed tomography showed a superior vena cava syndrome secondary to a mediastinal mass. Considering the severity of the obstruction, the absence of histological diagnosis and distant metastasis, an endovascular stent was placed urgently, with rapid clinical improvement. Subsequently, we obtained a diagnosis of stage IIIA lung adenocarcinoma. After partial response to chemoradiotherapy, the patient started consolidation therapy with durvalumab. Six months after the diagnosis, there is no relapse.","PeriodicalId":484795,"journal":{"name":"Revista do Grupo de Estudos do Cancro do Pulmão","volume":"26 2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136184629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}